Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics Expects $27.7M in Net Proceeds from Public Offering

NEW YORK (GenomeWeb News) – Rosetta Genomics said in a regulatory filing on Thursday that it anticipates raising about $27.7 million in a public offering.

In a document filed with the US Securities and Exchange Commission, the company did not price the offering, which it announced last month, but said it is offering 3 million shares. The $27.7 million assumes a public offering price of $10.15 — the last reported sale price of its common share on the Nasdaq on July 24. Net proceeds will increase by about $4.2 million if underwriters exercise an overallotment option.

Aegis Capital is listed as the underwriter in the offering.

Net proceeds will go toward operations and other general corporate purposes, including repayment of loans, working capital, intellectual property protection and enforcement, and R&D.

In June Rosetta netted proceeds of about $6 million from a direct offering.

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.